Kyushu University Academic Staff Educational and Research Activities Database
List of Papers
shigehiro ohdo Last modified date:2018.06.17

Professor / Clinical Pharmacy / Department of Pharmaceutical Health Care and Sciences / Faculty of Pharmaceutical Sciences


Papers
1. Takashi Matsunaga, Matsunaga Naoya, Naoki Kusunose, Eriko Ikeda, Hiroyuki Okazaki, Keisuke Kakimoto, Kengo Hamamura, Koyanagi Satoru, Shigehiro Ohdo, Angiotensin-II regulates dosing time-dependent intratumoral accumulation of macromolecular drug formulations via 24-h blood pressure rhythm in tumor-bearing mice, Biochemical and Biophysical Research Communications, https://doi.org/10.1016/j.bbrc.2017.11.162, 498, 1, 86-91, 2018.03, One approach to increasing pharmacotherapy effects is administering drugs at times of day when they are most effective and/or best tolerated. Circadian variation in expression of pharmacokinetics- and pharmacodynamics-related genes was shown to contribute to dosing time-dependent differences in therapeutic effects of small molecule drugs. However, influence of dosing time of day on effects of high molecular weight formulations, such as drugs encapsulated in liposomes, has not been studied in detail. This study demonstrates that blood pressure rhythm affects dosing time-dependent variation in effects of high molecular weight formulations. Systolic blood pressure in sarcoma 180-bearing mice showed significant 24-h oscillation. Intratumoral accumulation of fluorescein isothiocyanate-labeled bovine serum albumin (FITC-BSA), an indicator of tumor vascular permeability, varied with dosing time of day, matching phases of blood pressure circadian rhythm. Furthermore, intratumoral accumulation of liposome-encapsulated oxaliplatin (Lipo-L-OHP) increased with increases in systolic blood pressure. Our findings suggest that circadian blood pressure oscillations may be an important factor to consider in dosing strategies for macromolecular drugs and liposomes in cancer therapy..
2. Shoya Shiromizu, Naoki Kusunose, Matsunaga Naoya, Koyanagi Satoru, Shigehiro Ohdo, Optimizing the dosing schedule of L-asparaginase improves its anti-tumor activity in breast tumor-bearing mice, Journal of Pharmacological Sciences, https://doi.org/10.1016/j.jphs.2018.01.008, 2018.01, Proliferation of acute lymphoblastic leukemic cells is nutritionally dependent on the external supply of asparagine. L-asparaginase, an enzyme hydrolyzing L-asparagine in blood, is used for treatment of acute lymphoblastic leukemic and other related blood cancers. Although previous studies demonstrated that L-asparaginase suppresses the proliferation of cultured solid tumor cells, it remains unclear whether this enzyme prevents the growth of solid tumors in vivo. In this study, we demonstrated the importance of optimizing dosing schedules for the anti-tumor activity of L-asparaginase in 4T1 breast tumor-bearing mice. Cultures of several types of murine solid tumor cells were dependent on the external supply of asparagine. Among them, we selected murine 4T1 breast cancer cells and implanted them into BALB/c female mice kept under standardized light/dark cycle conditions. The growth of 4T1 tumor cells implanted in mice was significantly suppressed by intravenous administration of L-asparaginase during the light phase, whereas its administration during the dark phase failed to show significant anti-tumor activity. Decreases in plasma asparagine levels due to the administration of L-asparaginase were closely related to the dosing time-dependency of its anti-tumor effects. These results suggest that the anti-tumor efficacy of L-asparaginase in breast tumor-bearing mice is improved by optimizing the dosing schedule..
3. Ken Ichi Hashikawa, Chiharu Katamune, Naoki Kusunose, Matsunaga Naoya, Koyanagi Satoru, Shigehiro Ohdo, Dysfunction of the circadian transcriptional factor CLOCK in mice resists chemical carcinogen-induced tumorigenesis, Scientific Reports, https://doi.org/10.1038/s41598-017-10599-1, 7, 1, 2017.12, The chronic disruption of circadian rhythms has been implicated in the risk of cancer development in humans and laboratory animals. The gene product CLOCK is a core molecular component of the circadian oscillator, so that mice with a mutated Clock gene (Clk/Clk) exhibit abnormal rhythms in various physiological processes. However, we demonstrated here that Clk/Clk mice resisted chemical carcinogen-induced tumorigenesis by suppressing epidermal growth factor (EGF) receptor-mediated proliferation signals. The repetitive application of 7,12-dimethylbenz[α]anthracene (DMBA) to skin on the back resulted in the significant development of tumors in wild-type mice, whereas chemically-induced tumorigenesis was alleviated in Clk/Clk mice. Although the degree of DMBA-induced DNA damage was not significantly different between wild-type and Clk/Clk mice, EGF receptor-mediated Ras activation was not detected in DMBA-treated Clk/Clk mice. Genetic and biochemical experiments revealed that the suppression of EGF receptor-mediated signal transduction in DMBA-treated Clk/Clk mice was associated with the expression of the cellular senescence factor p16INK4a. These results suggest an uncovered role for CLOCK in the development of chemical carcinogen-induced primary tumors and offers new preventive strategies..
4. Adila Dilixiati, Koyanagi Satoru, Naoki Kusunose, Matsunaga Naoya, Shigehiro Ohdo, Dietary supplementation with essence of chicken enhances daily oscillations in plasma glucocorticoid levels and behavioral adaptation to the phase-shifted environmental light–dark cycle in mice, Journal of Pharmacological Sciences, https://doi.org/10.1016/j.jphs.2017.07.004, 134, 4, 211-217, 2017.08, Maintenance of circadian rhythms is essential to many aspects of human health, including metabolism and neurological and psychiatric well-being. Chronic disruption of circadian clock function is implicated in increasing the risk of metabolic syndrome, cardiovascular events and development of cancers. However, there are little approaches to reinforce the function of circadian clock for prevention of these diseases. Essence of Chicken (EC) is a nutritional supplement that is traditionally made by extracting water soluble substances derived from cooking the whole chicken. In this study, we found that dietary supplementation with EC enhanced circadian oscillation of glucocorticoid secretion in mice, and this was accompanied by enhancement of circadian oscillation in the adrenal expression of steroidogenic acute regulatory (StAR) protein that mediates the rate-limiting step of glucocorticoid synthesis. Furthermore, EC facilitated re-entrainment of behavioral rhythm in mice when phase of the light–dark cycle was suddenly advanced. These results suggest that intake of EC has enhancement effect on circadian clock function in mice, which may contribute to sustain health and also offer new preventive strategies against circadian-related diseases..
5. Tomohiro Shibata, Kosuke Watari, Hiroto Izumi, Akihiko Kawahara, Satoshi Hattori, Chihiro Fukumitsu, Yuichi Murakami, Ryuji Takahashi, Uhi Toh, Ken Ichi Ito, Shigehiro Ohdo, Maki Tanaka, Masayoshi Kage, Michihiko Kuwano, Mayumi Ono, Breast cancer resistance to antiestrogens is enhanced by increased ER degradation and ERBB2 expression, Cancer Research, https://doi.org/10.1158/0008-5472.CAN-16-1593, 77, 2, 545-556, 2017.01, Endocrine therapies effectively improve the outcomes of patients with estrogen receptor (ER)-positive breast cancer. However, the emergence of drug-resistant tumors creates a core clinical challenge. In breast cancer cells rendered resistant to the antiestrogen fulvestrant, we defined causative mechanistic roles for the transcription factor YBX1 and the levels of ER and the ERBB2 receptor. Enforced expression of YBX1 in parental cells conferred resistance against tamoxifen and fulvestrant in vitro and in vivo. Furthermore, YBX1 overexpression was associated with decreased and increased levels of ER and ERBB2 expression, respectively. In antiestrogen-resistant cells, increased YBX1 phosphorylation was associated with a 4-fold higher degradation rate of ER. Notably, YBX1 bound the ER, leading to its accelerated proteasomal degradation, and induced the transcriptional activation of ERBB2. In parallel fashion, tamoxifen treatment also augmented YBX1 binding to the ERBB2 promoter to induce increased ERBB2 expression. Together, these findings define a mechanism of drug resistance through which YBX1 contributes to antiestrogen bypass in breast cancer cells..
6. Takumi Kanemitsu, Yuya Tsurudome, Naoki Kusunose, Masayuki Oda, Matsunaga Naoya, Koyanagi Satoru, Shigehiro Ohdo, Periodic variation in bile acids controls circadian changes in uric acid via regulation of xanthine oxidase by the orphan nuclear receptor PPARα, Journal of Biological Chemistry, https://doi.org/10.1074/jbc.M117.791285, 292, 52, 21397-21406, 2017.01, Xanthine oxidase (XOD), also known as xanthine dehydrogenase, is a rate-limiting enzyme in purine nucleotide degradation, which produces uric acid. Uric acid concentrations in the blood and liver exhibit circadian oscillations in both humans and rodents; however, the underlying mechanisms remain unclear. Here, we demonstrate that XOD expression and enzymatic activity exhibit circadian oscillations in the mouse liver. We found that the orphan nuclear receptor peroxisome proliferator-activated receptor-α (PPARα) transcriptionally activated the mouse XOD gene and that bile acids suppressed XOD transactivation. The synthesis of bile acids is known to be under the control of the circadian clock, and we observed that the time-dependent accumulation of bile acids in hepatic cells interfered with the recruitment of the co-transcriptional activator p300 to PPARα, thereby repressing XOD expression. This time-dependent suppression of PPARα-mediated transactivation by bile acids caused an oscillation in the hepatic expression of XOD, which, in turn, led to circadian alterations in uric acid production. Finally, we also demonstrated that the anti-hyperuricemic effect of the XOD inhibitor febuxostat was enhanced by administering it at the time of day before hepatic XOD activity increased. These results suggest an underlying mechanism for the circadian alterations in uric acid production and also underscore the importance of selecting an appropriate time of day for administering XOD inhibitors..
7. Yuya Sakamoto, Takahisa Yano, Yuki Hanada, Aki Takeshita, Fumika Inagaki, Satohiro Masuda, Matsunaga Naoya, Koyanagi Satoru, Shigehiro Ohdo, Vancomycin induces reactive oxygen species-dependent apoptosis via mitochondrial cardiolipin peroxidation in renal tubular epithelial cells, European Journal of Pharmacology, https://doi.org/10.1016/j.ejphar.2017.02.025, 800, 48-56, 2017.01, Vancomycin (VCM) is a first-line antibiotic for serious infections caused by methicillin-resistant Staphylococcus aureus. However, nephrotoxicity is one of the most complaint in VCM therapy. We previously reported that VCM induced apoptosis in a porcine proximal tubular epithelial cell line (LLC-PK1), in which mitochondrial complex I may generate superoxide, leading to cell death. In the present study, VCM caused production of mitochondrial reactive oxygen species and peroxidation of the mitochondrial phospholipid cardiolipin that was reversed by administration of the mitochondrial uncoupler carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP). FCCP also significantly suppressed VCM-induced depolarization of the mitochondrial membrane and apoptosis. Moreover, the lipophilic antioxidant vitamin E and a mitochondria-targeted antioxidant, mitoTEMPO, also significantly suppressed VCM-induced depolarization of mitochondrial membrane and apoptosis, whereas vitamin C, n-acetyl cysteine, or glutathione did not provide significant protection. These findings suggest that peroxidation of the mitochondrial membrane cardiolipin mediated the VCM-induced production of intracellular reactive oxygen species and initiation of apoptosis in LLC-PK1 cells. Furthermore, regulation of mitochondrial function using a mitochondria-targeted antioxidant, such as mitoTEMPO, may constitute a potential strategy for mitigation of VCM-induced proximal tubular epithelial cell injury..
8. Matsunaga Naoya, Eriko Ikeda, Keisuke Kakimoto, Miyako Watanabe, Naoya Shindo, Akito Tsuruta, Hisako Ikeyama, Kengo Hamamura, Kazuhiro Higashi, Tomohiro Yamashita, Hideaki Kondo, Yuya Yoshida, Masaki Matsuda, Takashi Ogino, Kazutaka Tokushige, Kazufumi Itcho, Yoko Furuichi, Takaharu Nakao, Kaori Yasuda, Atsushi Doi, Toshiaki Amamoto, Hironori Aramaki, Tsuda Makoto, Kazuhide Inoue, Akio Ojida, Koyanagi Satoru, Shigehiro Ohdo, Inhibition of G0/G1 Switch 2 Ameliorates Renal Inflammation in Chronic Kidney Disease, EBioMedicine, https://doi.org/10.1016/j.ebiom.2016.10.008, 13, 262-273, 2016.11, Chronic kidney disease (CKD) is a global health problem, and novel therapies to treat CKD are urgently needed. Here, we show that inhibition of G0/G1 switch 2 (G0s2) ameliorates renal inflammation in a mouse model of CKD. Renal expression of chemokine (C-C motif) ligand 2 (Ccl2) was increased in response to p65 activation in the kidneys of wild-type 5/6 nephrectomy (5/6Nx) mice. Moreover, 5/6Nx Clk/Clk mice, which carry homozygous mutations in the gene encoding circadian locomotor output cycles kaput (CLOCK), did not exhibit aggravation of apoptosis or induction of F4/80-positive cells. The renal expression of G0s2 in wild-type 5/6Nx mice was important for the transactivation of Ccl2 by p65. These pathologies were ameliorated by G0s2 knockdown. Furthermore, a novel small-molecule inhibitor of G0s2 expression was identified by high-throughput chemical screening, and the inhibitor suppressed renal inflammation in 5/6Nx mice. These findings indicated that G0s2 inhibitors may have applications in the treatment of CKD..
9. Koyanagi Satoru, Naoki Kusunose, Marie Taniguchi, Takahiro Akamine, Yuki Kanado, Yui Ozono, Takahiro Masuda, Yuta Koro, Matsunaga Naoya, Tsuda Makoto, Michael W. Salter, Kazuhide Inoue, Shigehiro Ohdo, Glucocorticoid regulation of ATP release from spinal astrocytes underlies diurnal exacerbation of neuropathic mechanical allodynia, Nature Communications, https://doi.org/10.1038/ncomms13102, 7, 2016.10, Diurnal variations in pain hypersensitivity are common in chronic pain disorders, but the underlying mechanisms are enigmatic. Here, we report that mechanical pain hypersensitivity in sciatic nerve-injured mice shows pronounced diurnal alterations, which critically depend on diurnal variations in glucocorticoids from the adrenal glands. Diurnal enhancement of pain hypersensitivity is mediated by glucocorticoid-induced enhancement of the extracellular release of ATP in the spinal cord, which stimulates purinergic receptors on microglia in the dorsal horn. We identify serum- and glucocorticoid-inducible kinase-1 (SGK-1) as the key molecule responsible for the glucocorticoid-enhanced release of ATP from astrocytes. SGK-1 protein levels in spinal astrocytes are increased in response to glucocorticoid stimuli and enhanced ATP release by opening the pannexin-1 hemichannels. Our findings reveal an unappreciated circadian machinery affecting pain hypersensitivity caused by peripheral nerve injury, thus opening up novel approaches to the management of chronic pain..
10. Elsayed M, Kobayashi D, Kubota T, Matsunaga N, Murata R, Yoshizawa Y, Watanabe N, Matsuura T, Tsurudome Y, Ogino T, Ohdo S, Shimazoe T., Synergistic Antiproliferative Effects of Zoledronic Acid and Fluvastatin on Human Pancreatic Cancer Cell Lines: An in Vitro Study. Biol Pharm Bull. 2016 Aug 1;39(8):1238-1246., Biol Pharm Bull. 2016 Aug 1;39(8):1238-1246., Biol Pharm Bull. 2016 Aug 1;39(8):1238-1246., 2016.08.
11. Katamune C, Koyanagi S, Shiromizu S, Matsunaga N, Shimba S, Shibata S, Ohdo S. , Different Roles of Negative and Positive Components of the Circadian Clock in Oncogene-induced Neoplastic Transformation., J Biol Chem. 2016 May 13;291(20):10541-10550., J Biol Chem. 2016 May 13;291(20):10541-10550., 2016.05.
12. Hamamura K, Matsunaga N, Ikeda E, Kondo H, Ikeyama H, Tokushige K, Itcho K, Furuichi Y, Yoshida Y, Matsuda M, Yasuda K, Doi A, Yokota Y, Amamoto T, Aramaki H, Irino Y, Koyanagi S, Ohdo S., Alterations of Hepatic Metabolism in Chronic Kidney Disease via D-box-binding Protein Aggravate the Renal Dysfunction. J Biol Chem. 2016 Mar 4;291(10):4913-4927., J Biol Chem. 2016 Mar 4;291(10):4913-4927., J Biol Chem. 2016 Mar 4;291(10):4913-4927., 2016.03.
13. Okazaki F, Matsunaga N, Okazaki H, Azuma H, Hamamura K, Tsuruta A, Tsurudome Y, Ogino T, Hara Y, Suzuki T, Hyodo K, Ishihara H, Kikuchi H, To H, Aramaki H, Koyanagi S, Ohdo S., Circadian Clock in a Mouse Colon Tumor Regulates Intracellular Iron Levels to Promote Tumor Progression. J Biol Chem. 2016 Mar 25;291(13):7017-7028., J Biol Chem. 2016 Mar 25;291(13):7017-7028., J Biol Chem. 2016 Mar 25;291(13):7017-7028., 2016.03.
14. Akamine T, Koyanagi S, Kusunose N, Hashimoto H, Taniguchi M, Matsunaga N, Ohdo S:, Dosing time-dependent changes in the analgesic effect of pregabalin on diabetic neuropathy in mice. , J Pharmacol Exp Ther 354: 65-72 (2015) , J Pharmacol Exp Ther 354: 65-72 (2015)






, 2015.09.
15. Iwasaki M, Koyanagi S, Suzuki N, Katamune C, Matsunaga N, Watanabe N, Takahashi M, Izumi T, Ohdo S:, Circadian modulation in the intestinal absorption of P-glycoprotein substrates in monkeys. Mol Pharmacol 88: 29-37 (2015)

, Mol Pharmacol 88: 29-37 (2015) , Mol Pharmacol 88: 29-37 (2015)





, 2015.07.
16. Wada E, Koyanagi S, Kusunose N, Akamine T, Masui H, Hashimoto H, Matsunaga N, Ohdo S., Modulation of peroxisome proliferator-activated receptor-α activity by bile acids causes circadian changes in the intestinal expression of Octn1/Slc22a4 in mice.

, Mol Pharmacol. 2015 Feb;87(2):314-22. , Mol Pharmacol. 2015 Feb;87(2):314-22.




, 2015.02.
17. Sonoki K, Iwase M, Ohdo S, Ieiri I, Takata Y, Kitazono T., Statin inhibits the expression of secretory phospholipase A2 and subsequent monocyte chemoattractant protein-1 in human endothelial cells. , J Cardiovasc Pharmacol. 2014 Dec;64(6):489-96. , J Cardiovasc Pharmacol. 2014 Dec;64(6):489-96.



, 2014.12.
18. Okamura A, Koyanagi S, Dilxiat A, Kusunose N, Chen JJ, Matsunaga N, Shibata S, Ohdo S., Bile acid-regulated peroxisome proliferator-activated receptor-α (PPARα) activity underlies circadian expression of intestinal peptide absorption transporter PepT1/Slc15a1.

, J Biol Chem. 2014 Sep 5;289(36):25296-305. , J Biol Chem. 2014 Sep 5;289(36):25296-305.

, 2014.09.
19. Matsunaga N, Itcho K, Hamamura K, Ikeda E, Ikeyama H, Furuichi Y, Watanabe M, Koyanagi S, Ohdo S. , 24-hour rhythm of aquaporin-3 function in the epidermis is regulated by molecular clocks.


, J Invest Dermatol. , J Invest Dermatol. 2014 Jun;134(6):1636-1644.  doi: 10.1038/jid.2014.13. Epub 2014 Jan 13.
, 2014.06.
20. Oda M, Koyanagi S, Tsurudome Y, Kanemitsu T, Matsunaga N, Ohdo S. , Renal circadian clock regulates the dosing-time dependency of cisplatin-induced nephrotoxicity in mice.


, Mol Pharmacol. , Mol Pharmacol. 2014 May;85(5):715-722.   doi: 10.1124/mol.113.089805. Epub 2014 Feb 24.
, 2014.05.
21. Okazaki H, Matsunaga N, Fujioka T, Okazaki F, Akagawa Y, Tsurudome Y, Ono M, Kuwano M, Koyanagi S, Ohdo S. , Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma.

, Cancer Res. , Cancer Res. 2014 Jan 15;74(2):543-551. doi: 10.1158/0008-5472.CAN-12-3241. Epub 2013 Nov 19. Erratum in: Cancer Res. 2014 Mar 1;74(5):1621.


, 2014.01.
22. Karakawa S, Miyoshi Y, Konno R, Koyanagi S, Mita M, Ohdo S, Hamase K., Two-dimensional high-performance liquid chromatographic determination of day-night variation of D-alanine in mammals and factors controlling the circadian changes.


, Anal Bioanal Chem. , Anal Bioanal Chem. 2013 405(25), 8083-8091.
, 2013.10.
23. Hayashi Y, Koyanagi S, Kusunose N, Okada R, Wu Z, Tozaki-Saitoh H, Ukai K, Kohsaka S, Inoue K, Ohdo S, Nakanishi H. , The intrinsic microglial molecular clock controls synaptic strength via the circadian expression of cathepsin S.


, Sci Rep. , Sci Rep. 2013 Sep 25;3:2744. doi: 10.1038/srep02744.
, 2013.09.
24. Hayashi A, Matsunaga N, Okazaki H, Kakimoto K, Kimura Y, Azuma H, Ikeda E, Shiba T, Yamato M, Yamada K, Koyanagi S, Ohdo S. A disruption mechanism of the molecular clock in a MPTP mouse model of Parkinson' , A disruption mechanism of the molecular clock in a MPTP mouse model of Parkinson's disease.





, Neuromolecular Med , Neuromolecular Med 15(2), 238-251, 2013. , 2013.06.
25. Ikeda E, Matsunaga N, Kakimoto K, Hamamura K, Hayashi A, Koyanagi S, Ohdo S. , Molecular mechanism regulating 24-hour rhythm of dopamine D3 receptor expression in mouse ventral striatum.



, Mol Pharmacol , Mol Pharmacol 83(5), 959-967, 2013. , 2013.05.
26. Ogi S, Fujita H, Kashihara M, Yamamoto C, Sonoda K, Okamoto I, Nakagawa K, Ohdo S, Tanaka Y, Kuwano M, Ono M. , Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular-targeted drugs.




, Cancer Sci , Cancer Sci 104(5), 573-583, 2013 .
, 2013.05.
27. 赤嶺孝祐、 若松菜摘、 横山絵里、 松永直哉、 小柳悟、 大戸茂弘.  , ゲムシタビン注射用製剤 後発医薬品の溶解性に関する検討.

, 医療薬学 , 医療薬学39, 4, 220-224, 2013. 

, 2013.04.
28. Kuroki K, Hirose K, Okabe Y, Fukunaga Y, Takahashi A, Shiroishi M, Kajikawa M, Tabata S, Nakamura S, Takai T, Koyanagi S, Ohdo S, Maenaka K. , The long-term immunosuppressive effects of disulfide-linked HLA-G dimer in mice with collagen-induced arthritis.
, Hum Immunol , Hum Immunol 74(4), 433-438, 2013.

, 2013.04.
29. Horiguchi M, Koyanagi S, Hamdan AM, Kakimoto K, Matsunaga N, Yamashita C, Ohdo S. , Rhythmic control of the ARF-MDM2 pathway by ATF4 underlies circadian accumulation of p53 in malignant cells.

, Cancer Res , Cancer Res 73(8), 2639-2649, 2013.
, 2013.04.
30. Tomishima Y, Ishitsuka Y, Matsunaga N, Nagatome M, Furusho H, Irikura M, Ohdo S, Irie T. , Ozagrel hydrochloride, a selective thromboxane A₂ synthase inhibitor, alleviates liver injury induced by acetaminophen overdose in mice., BMC Gastroenterol , BMC Gastroenterol 2013 Jan 30;13:21. doi: 10.1186/1471-230X-13-21.
, 2013.01.
31. Noda M, Yamakawa Y, Matsunaga N, Naoe S, Jodoi T, Yamafuji M, Akimoto N, Teramoto N, Fujita K, Ohdo S, Iguchi H. , IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain.

, Int J Mol Sci , Int J Mol Sci 14(1), 515-526, 2012.
, 2012.12.
32. Kaneshige S, Kobayashi M, Matsunaga N,Koyanagi S, Ohdo S, Kamimura H. , Pharmaceutical and therapeutic equivalence study of the generic medicine containing loxoprofen sodium. , Japanese Pharmacology & Therapeutics , Japanese Pharmacology & Therapeutics 40(12), 1081-1088, 2012. , 2012.12.
33. Sonoki K, Iwase M, Ohdo S, Ieiri I, Matsuyama N, Takata Y, Kitazono T. , Telmisartan and N-acetylcysteine suppress group V secretory phospholipase A2 expression in TNFα-stimulated human endothelial cells and reduce associated atherogenicity.
, J Cardiovasc Pharmacol , J Cardiovasc Pharmacol 60(4), 367-374, 2012.
, 2012.10.
34. Nakaya M, Chikura S, Watari K, Mizuno N, Mochinaga K, Mangmool S, Koyanagi S, Ohdo S, Sato Y, Ide T, Nishida M, Kurose H. , Induction of cardiac fibrosis by β-blocker in G protein-independent and G protein-coupled receptor kinase 5/β-arrestin2-dependent Signaling pathways.
, J Biol Chem , J Biol Chem 287(42), 35669-35677, 2012.
, 2012.10.
35. Ushijima K, Koyanagi S, Sato Y, Ogata T, Matsunaga N, Fujimura A, Ohdo S. , Role of activating transcription factor-4 in 24-hour rhythm of serotonin transporter expression in the mouse midbrain.

, Mol Pharmacol , Mol Pharmacol 82(2), 264-270, 2012.
, 2012.08.
36. Matsunaga N, Inoue M, Kusunose N, Kakimoto K, Hamamura K, Hanada Y, Toi A, Yoshiyama Y, Sato F, Fujimoto K, Koyanagi S, Ohdo S. , Time-dependent interaction between differentiated embryo chondrocyte-2 and CCAAT/enhancer-binding protein α underlies the circadian expression of CYP2D6 in serum-shocked HepG2 cells. , Mol Pharmacol , Mol Pharmacol 81(5): 739-747, 2012., 2012.05.
37. Hamdan AM, Koyanagi S, Wada E, Kusunose N, Murakami Y, Matsunaga N, Ohdo S. , Intestinal expression of mouse Abcg2/Bcrp gene is under the control of circadian clock-activating transcription factor-4 pathway. , J Biol Chem., J Biol Chem. 18; 287(21):17224-17231. 2012 , 2012.05.
38. Horiguchi M, Koyanagi S, Okamoto A, Suzuki SO, Matsunaga N, Ohdo S., Stress-regulated transcription factor ATF4 promotes neoplastic transformation by suppressing expression of the INK4a/ARF cell senescence factors., Cancer Res. , Cancer Res. 72(2), 395-401, 2012., 2012.01.
39. Tanimura N, Kusunose N, Matsunaga N, Koyanagi S, Ohdo S. , Aryl hydrocarbon receptor-mediated Cyp1a1 expression is modulated in a CLOCK-dependent circadian manner., Toxicology, Toxicology. 290(2-3), 203-207, 2011., 2011.12.
40. Koyanagi S, Hamdan AM, Horiguchi M, Kusunose N, Okamoto A, Matsunaga N, Ohdo S. , cAMP-response element (CRE)-mediated transcription by activating transcription factor-4 (ATF4) is essential for circadian expression of the Period2 gene., J Biol Chem. , J Biol Chem. 286(37), 32416-32423, 2011., 2011.09.
41. Tsuda M, Kohro Y, Yano T, Tsujikawa T, Kitano J, Tozaki-Saitoh H, Koyanagi S, Ohdo S, Ji RR, Salter MW, Inoue K. , JAK-STAT3 pathway regulates spinal astrocyte proliferation and neuropathic pain maintenance in rats., Brain, Epub 2011 Mar 2., 134, (Pt 4), 1127-1139, 2011 Apr;134(Pt 4):1127-1139. Epub 2011 Mar 2.
, 2011.04.
42. Matsunaga N, Kohno Y, Kakimoto K, Hayashi A, Koyanagi S, Ohdo S. , Influence of CLOCK on cytotoxicity induced by diethylnitrosamine in mouse primary hepatocytes. , Toxicology 280(3),144 -151, 2011. , 280(3),144 -151, 2011. , 2011.02.
43. 兼重晋、池田祐輔、松永直哉、小柳悟、大戸茂弘、神村英利., ベザフィブラート後発医薬品の製剤学的および治療学的同等性試験., 薬理と治療 , 39(1),91-100,2011., 2011.01.
44. 兼重晋、有馬希、松永直哉、小柳悟、大戸茂弘、神村英利., グリクラジド後発医薬品の製剤学的および治療学的同等性試験., 薬理と治療 , 38(12),1133-1141,2010., 2010.12.
45. Kusunose N, Koyanagi S, Hamamura K, Matsunaga N, Yoshida M, Uchida T, Tsuda M, Inoue K, Ohdo S. , Molecular basis for the dosing time-dependency of anti-allodynic effects of gabapentin in a mouse model of neuropathic pain., Mol Pain , 6, 83, 2010., 2010.11.
46. Hayashida S, Kuramoto Y, Koyanagi S, Oishi K, Fujiki J, Matsunaga N, Ikeda E, Ohdo S, Shimeno H, Soeda S. , Proxisome proliferator-activated receptor-α mediates high-fat, diet-enhanced daily oscillation of plasminogen activator inhibitor-1 activity in mice., Chronobiol Int , 27(9-10), 1735-1753, 2010., 2010.10.
47. Okazaki F, Matsunaga N, Okazaki H, Utoguchi N, Suzuki R, Maruyama K, Koyanagi S, Ohdo S. , Circadian rhythm of transferrin receptor 1 gene expression controlled by c-Myc in colon cancer-bearing mice. , Cancer Res , 70(15), 6238-6246, 2010., 2010.08, 癌細胞のトランスフェリン受容体発現リズムの制御機構を解明 ~癌の新規治療法へ期待~ 
癌細胞の増殖にかかわるトランスフェリン受容体の発現に日周リズムがあり,その発現リズムが癌遺伝子c-Mycにより制御されることを世界で初めて突き止めた。また、トランスフェリン受容体発現リズムを指標としたトランスフェリンリポソーム製剤の新規時間薬物送達方法の構築に成功した。この研究成果によって、癌の生体リズム研究が一層進展すること、さらに、ドラッグデリバリーシステム(DDS)を応用した新規の癌の時間薬物療法の開発に繋がることが期待される。.
48. Oishi K, Koyanagi S, Matsunaga N, Kadota K, Ikeda E, Hayashida S, Kuramoto Y, Shimeno H, Soeda S, Ohdo S. , Bezafibrate induces plasminogen activator inhibitor-1 gene expression in a CLOCK-dependent circadian manner., Mol Pharmacol , 78(1), 135-141, 2010., 2010.07.
49. Fujioka T, Matsunaga N, Okazaki H, Koyanagi S, Ohdo S. , Hypoxia-response plasmid vector producing bcl-2 shRNA enhances the apoptotic cell death of mouse rectum carcinoma. J Pharmacol Sci. 113(4), 353-361, 2010., J Pharmacol Sci. , 113(4), 353-361, 2010., 2010.07.
50. Horiguchi M, Kim J, Matsunaga N, Kaji H, Egawa T, Makino K, Koyanagi S, Ohdo S., Glucocorticoid-dependent expression of O6-methylguanine-DNA methyltransferase gene modulates the dacarbazine-induced hepatotoxicity in mice. , J Pharmacol Exp Ther , 2010 Mar 22. [Epub ahead of print]
, 2010.03.
51. Sonoki K, Iwase M, Sasaki N, Ohdo S, Higuchi S, Matsuyama N, Iida M. , Relations of lysophosphatidylcholine in low-density lipoprotein with serum lipoprotein-associated phospholipase A2, paraoxonase and homocysteine thiolactonase activities in patients with type 2 diabetes mellitus. , Diabetes Res Clin Pract. , 86,117-123, 2009
, 2009.11.
52. Ohdo S, Matsunaga N, Koyanagi S. , Molecular clock mechanisms of drug metabolism.
, 16th International Conference on Cytochrome P450: Functional genomics , 149-154, 2009.


, 2009.11.
53. Kim J, Matsunaga N, Koyanagi S, Ohdo S. , Clock gene mutation modulates the cellular sensitivity to genotoxic stress through altering the expression of N-methylpurine DNA glycosylase gene. 
, Biochem Pharmacol., 78(8),1075-1082, 2009
, 2009.10.
54. Burioka N, Koyanagi S, Fukuoka Y, Okazaki F, Fujioka T, Kusunose N, Endo M, Suyama H, Chikumi H, Ohdo S, Shimizu E. , Influence of intermittent hypoxia on the signal transduction pathways to inflammatory response and circadian clock regulation. , Life Sci., 85,372-378, 2009, 2009.08.
55. Tojo Y, Hamase K, Konno R, Koyanagi S, Ohdo S, Zaitsu K. , Simple and rapid genotyping of D-amino acid oxidase gene recognizing a crucial variant in the ddY strain using microchip electrophoresis. , J Sep Sci. , 32(3), 430-436, 2009., 2009.02.
56. Akagi T, Fukagawa T, Kage Y, To H, Matsunaga N, Koyanagi S, Uchida A, Fujii A, Iba H, Ikemura T, Aramaki H, Higuchi S, Ohdo S. , Role of glucocorticoid receptor in the regulation of cellular sensitivity to irinotecan hydrochloride., J Pharmacol Sci. , 109(2), 265-274, 2009., 2009.02.
57. Nakagawa H., Koyanagi S., Kuramoto Y., Yoshizumi A., Matsunaga N., Shimeno H., Soeda S., Ohdo S. , Modulation of circadian rhythm of DNA synthesis in tumor cells by inhibiting platelet-derived growth factor signaling., J Pharmacol Sci. , 107, 401-407, 2008., 2008.09.
58. Shinohara A., Koyanagi S., Hamdan AM., Matsunaga N., Aramaki H., Ohdo S., Dosing schedule-dependent change in the disruptive effects of interferon-α on the circadian clock function., Life Sci. , 83, 574-580, 2008 ., 2008.09.
59. Murakami Y., Higashi Y., Matsunaga N., Koyanagi S., Ohdo S., Circadian clock-controlled intestinal expression of the multidrug-resistance gene mdr1a in mice.
, Gastroenterology , 135, 1636-1644, 2008.
, 2008.09.
60. Sakaguchi, H., Kodama, A., Tomonari, M., Ando, Y., Tabuchi, M., To, H., Araki, R., Kitahara, T., Sasaki, H., Ohdo, S., Higuchi, S. , Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity. , Breast Cancer Res. Treat. , 109, 443-450, 2008., 2008.04.
61. Sonoki, K., Iwase, M., Sasaki, N., Ohdo, S., Higuchi, S., Takata, Y., Iida, M., Secretory PLA(2) inhibitor indoxam suppresses LDL modification and associated inflammatory responses in TNFα-stimulated human endothelial cells., Br. J. Pharmacol. , 153, 1399-1408, 2008 . , 2008.04.
62. Burioka, N., Koyanagi, S., Endo, M., Takata, M., Fukuoka, Y., Miyata, M., Takeda, K., Chikumi, H., Ohdo, S., Shimizu, E. , Clock gene dysfunction in patients with obstructive sleep apnoea syndrome. , Eur. Respir. J. , 32, 105-112, 2008., 2008.04.
63. Morikawa, A., Hamase, K., Miyoshi, Y., Koyanagi, S., Ohdo, S., Zaitsu, K. , Circadian changes of D-alanine and related compounds in rats and the effect of restricted feeding on their amounts. , J. Chromatography B , 875, 168-173, 2008., 2008.04.
64. Matsunaga, N., Ikeda, M., Takiguchi, T., Koyanagi, S., Ohdo, S., The molecular mechanism regulating 24-hour rhythm of CYP2E1 expression in the mouse liver. , Hepatology , 48, 240-251, 2008., 2008.04.
65. Terazono, H., Hamdan, A., Matsunaga, N., Hayasaka, N., Kaji, H., Egawa, T., Makino, K., Shigeyoshi, Y., Koyanagi, S., Ohdo, S., Modulatory effects of 5-fluorouracil on the rhythmic expression of circadian clock genes: A possible mechanism of chemotherapy-induced circadian rhythm disturbances. , Biochem. Pharmacol. , 75, 1616-1622, 2008. , 2008.03.
66. Iwase, M., Sonoki, K., Sasaki, N., Ohdo, S., Higuchi, S., Hattori, H., Iida, M., Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: Relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment. , Atherosclerosis , 196, 931-936, 2008., 2008.01.
67. Takiguchi, T., Tomita, M., Matsunaga, N., Nakagawa, H., Koyanagi, S., Ohdo, S. , Molecular basis for rhythmic expression of CYP3A4 in serum-shocked HepG2 cells. , Pharmacogenetics and Genomics , 17(12), 1047-1056, 2007.
, 2007.12.
68. Yamasaki, D., Tsujimoto, M., Ohdo, S., Ohtani, H., Sawada, Y., Possible mechanisms for the pharmacokinetic interaction between phenytoin and folinate in rats. , Therapeutic Drug Monitoring , 29(4), 404-411, 2007. , 2007.08.
69. Tanaka, C., Ohtani, H., Tsujimoto, M., Ohdo, S., Taniguchi, M., Mizooku, Y., Saitoh, Y., Kimura,,M. Uchimaru, H., Irie, S., Sawada, Y. , Effects of dosing interval on the pharmacokinetic interaction between oral small spherical activated charcoal and amlodipine in humans., Journal of Clinical Pharmacology , 47, 904-908, 2007., 2007.07.
70. Kanno, M., Araie, M., Masuda, K., Takase, M., Kitazawa, Y., Shiose, Y., Azuma, I., Ogawa, N., Ohdo, S. , Phase III long-term study and comparative clinical study of nipradilol ophthalmic solution in patients with primary open-angle glaucoma and ocular hypertension. Part 2. , Arzneimittel-Forschung , 56(12), 820-825, 2006.12.
71. Nakagawa, H., Takiguchi, T., Nakamura, M., Furuyama, A., Koyanagi, S., Aramaki, H., Higuchi, S., Ohdo, S., Basis for dosing time-dependent change in the anti-tumor effect of imatinib in mice. , Biochemical Pharmacology, 72(10), 1237-1245, 2006.11.
72. Koyanagi, S., Suyama, H., Kuramoto, Y., Matsunaga, N., Takane, H., Soeda, S., Shimeno, H., Higuchi, S., Ohdo, S. , Glucocorticoid regulation of 24-hour oscillation in interferon receptor gene expression in mouse liver. , Endocrinology , 147(11), 5034-5040, 2006.11.
73. Kanno, M., Araie, M., Masuda, K., Takase, M., Kitazawa, Y., Shiose, Y., Azuma, I., Ogawa, N., Ohdo, S. , Phase III long-term study and comparative clinical study of nipradilol ophthalmic solution in patients with primary open-angle glaucoma and ocular hypertension. , Arzneimittel-Forschung , 56(11), 729-734, 2006.11.
74. Ushijima, K., Morikawa, T., To, H., Higuchi, S., Ohdo, S. , Chronobiological disturbances with hyperthermia and hypercortisolism induced by chronic mild stress in rats. , Behavioural Brain Research , 173(2), 326-330, 2006., 2006.10.
75. Yoshida, M., Kiyofuji, H., Koyanagi, S., Matsuo, A., Fujioka, T., To, H., Higuchi, S., Ohdo, S., Glucocorticoid is involved in food-entrainable rhythm of オ-opioid receptor expression in mouse brainstem and analgesic effect of morphine., Journal of Pharmacological Sciences, 101,77-84, 2006.05.
76. Koyanagi, S., Okazawa, S., Kuramoto, Y., Ushijima, K., Shimeno, H., Soeda, S., Okamura, H., Ohdo, S., Chronic treatment with prednisolone represses the circadian oscillation of clock gene expression in mouse peripheral tissues., Mol. Endocrinol., 20(3), 573-583, 2006.05.
77. Kuramoto, Y., Hata, K., Koyanagi, S., Ohdo, S., Shimeno, H., Soeda, S., Circadian regulation of mouse topoisomerase I gene expression by glucocorticoid hormones., Biochemical Pharmacology, 71, 1155-1161, 2006.04.
78. Fuchikami, H., Satoh, H., Tsujimoto, M., Ohdo, S., Ohtani, H., Sawada, Y. , Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. , Drug Metabolism & Disposition., 34(4), 577-582, 2006.04.
79. Yamauchi, A., Ichimiya, T., Inoue, K., Taguchi, Y., Matsunaga, N., Koyanagi, S., Fukagawa, T., Aramaki, H., Higuchi, S., Ohdo, S., Cell cycle dependent pharmacology of methotrexate in HL-60., Journal of Pharmacological Sciences, 10.1254/jphs.FP0050761, 99, 4, 335-341, 99,335-341, 2005.12.
80. Yoshida, M., Koyanagi, S., Matsuo, A., Fujioka, T., To, H., Higuchi, S., Ohdo, S., Glucocorticoid hormone regulates the circadian coordination of u-opioid receptor expression in mouse brainstem., Journal of Pharmacology and Experimental Therapeutics, 10.1124/jpet.105.091488, 315, 3, 1119-1124, 315(3), 1119-1124, 2005.12.
81. Fukuoka, Y., Burioka, N., Takata, M., Ohdo, S., Miyata, M., Endo, M., Shimizu, E., Glucocorticoid administration increases hPer1 mRNA levels in human peripheral blood mononuclear cells in vitro or in vivo., Journal of Biological Rhythms, 10.1177/0748730405279866, 20, 6, 550-553, 20(6), 550-553, 2005.12.
82. Ushijima K., Sakaguchi H., Sato Y., To H., Koyanagi S., Higuchi S., Ohdo S., Chronopharmacological study of antidepressants in forced swimming test of mice., Journal of Pharmacology and Experimental Therapeutics, 10.1124/jpet.105.088849, 315, 2, 764-770, 315(2), 764-770, 2005.11.
83. Takimoto M., Hamada A., Tomoda A., Ohdo S., Ohmura T., Sakato H., Kawatani J., Jodoi T., Nakagawa H., Terazono H., Koyanagi S., Higuchi S., Kimura M., Tukikawa H., Irie S., Saito H., Miike T., Daily expression of clock genes in whole blood cells in healthy subjects and a patient with circadian rhythm sleep disorder., Am. J. Physiol. Regul. Integr. Comp. Physiol., 10.1152/ajpregu.00216.2005, 289, 5, R1273-R1279, 289, 1273-1279, 2005.11.
84. Tabuchi, M., To, H., Sakaguchi, H., Goto N., Takeuchi, A., Higuchi, S., Ohdo, S., Therapeutic index by combination of adriamycin and docetaxel depends on dosing time in mice., Cancer Research., 10.1158/0008-5472.CAN-05-1161, 65, 18, 8448-8454, 2005.09.
85. Takata, M., Burioka, N., Ohdo, S., Fukuoka, Y., Miyata, M., Endo, M., Suyama, H., Shimizu, E., β2-adrenoceptor agonists induce the mammalian clock gene, hPer1, mRNA in cultured human bronchial epithelium cells in vitro., Chronobiology International, 10.1080/07420520500179167, 22, 4, 777-783, 22(4), 777-783, 2005.04.
86. Burioka, N., Takata, M., Okano, Y., Ohdo, S., Fukuoka, Y., Miyata, M., Takane, H., Endo, M., Suyama, H., Shimizu, E., Dexamethasone influences human clock gene expression in bronchial epithelium and peripheral blood mononuclear cells in vitro., Chronobiology International, 10.1081/CBI-200062416, 22, 3, 585-590, 22(3), 585-590, 2005.03.
87. Viyoch, J., Matsunaga, N., Yoshida, M., To, H., Higuchi, S., Ohdo, S., Effect of haloperidol on mPer1 gene expression in mouse SCN., Journal of Biological Chemistry, 10.1074/jbc.M411704200, 280, 8, 6309-6315, 280, 8, 6309-6315, 2005.02.
88. To, H., Saito, T., Ohdo, S., Higuchi, S., Fujimura, A., Kobayashi, E., Doxorubicin chronotherapy in Japanese outpatients with breast cancer., Drugs R D, 6(2), 101-107, 2005.02.
89. Matsunaga, N., Nakamura, N., Yoneda, N., Qin, T., Terazono, H., To, H., Higuchi, S., Ohdo, S., Influence of feeding schedule on 24-hr rhythm of hepatotoxicity induced by acetaminophen in mice., Journal of Pharmacology and Experimental Therapeutics, 10.1124/jpet.104.069062, 311, 2, 594-600, 311, 2, 594-600, 2004.11.
90. Nakagawa, H., Koyanagi, S., Takiguchi, T., Kuramoto, Y., Soeda, S., Shimeno, H., Higuchi, S., Ohdo, S., 24-hr oscillation of mouse methionine aminopeptidase2, a regulator of tumor progression, is regulated by clock gene proteins., Cancer Research, 10.1158/0008-5472.CAN-04-2122, 64, 22, 8328-8333, 64, 8328 - 8333, 2004.11.
91. To, H., Shin,M., Tabuchi, M., Sakaguchi, H., Takeuchi, A., Matsunaga,N., Higuchi, H., Ohdo, S., Influence of dosing schedule on toxicity and antitumor effect by combination of adriamycin and docetaxel in mice., Clinical Cancer Research, 10.1158/1078-0432.CCR-1000-03, 10, 2, 762-769, 10,762-769, 2004.01.
92. Akagi, T., Ushinohama, K., Ikesue, S., Yukawa, E., Higuchi, S., Hamase, K., Zaitsu, K., Ohdo, S., Chronopharmacology of melatonin in mice to maximize the antitumor effect and minimize the rhythm disturbance effect., Journal of Pharmacology and Experimental Therapeutics, 10.1124/jpet.103.055657, 308, 1, 378-384, 308, 1, 378-384, 2004.01.
93. Koyanagi, S., Kuramoto, Y., Nakagawa, H., Aramaki, H., Ohdo, S., Soeda, S., Shimeno, H., A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells., Cancer Research, 63, 21, 7277-7283, 63, 7277-7283, 2003.11.
94. Sonoki, K., Iwase, M., Lino, K., Ichikawa, K.,Yoshinari, M., Ohdo, S., Higuchi, S., Iida, M., Dilazep and fenofibric acid inhibit MCP-1 mRNA expression in glycoxidized LDL-stimulated human endothelial cells., European Journal of Pharmacology, 10.1016/S0014-2999(03)02109-5, 475, 1-3, 139-147, 475,139-147, 2003.08.
95. Yoshida, M., Ohdo, S., Takane, H., Tomiyoshi, Y., Matsuo, A., Yukawa, E., Higuchi, S., Chronopharmacology of analgesic effect and its tolerance induced by morphine in mice., Journal of Pharmacology and Experimental Therapeutics, 10.1124/jpet.103.049031, 305, 3, 1200-1205, 305, 3, 1200-1205, 2003.06.
96. To, H., Ohdo, S., Shin, M., Uchimaru, H., Yukawa, E., Higuchi, S., Fujimura, A., Kobayashi, E., Dosing-time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity in rats., Journal of Pharmacy and Pharmacology, 10.1211/0022357021116, 55, 6, 803-810, 55,803-810, 2003.06.
97. Terazono, H., Mutoh, T., Yamaguchi, S., Kobayashi, M., Akiyama, M., Udo, R., Ohdo, S., Okamura, H., Shibata, S., Adrenergic regulation of clock gene expression in mouse liver., Proc Natl Acad Sci, 10.1073/pnas.0936797100, 100, 11, 6795-6800, 100,11,6795-6800, 2003.05.
98. Sonoki, K., Iwase, M., Lino, K., Ichikawa, K., Ohdo, S., Higuchi, S., Yoshinari, M., Iida, M., Atherogenic role of lysophosphatidylcholine in low-density lipoprotein modified by phospholipase A(2) and in diabetic patients: Protection by nitric oxide donor., Metabolism, 10.1053/meta.2003.50049, 52, 3, 308-314, 52,3, 308-314, 2003.05.
99. Koyanagi, S., Nakagawa, H., Kuramoto, Y., Ohdo, S., Soeda, S., Shimeno, H., Optimizing the dosing schedule of TNP-470 [o-(chloroacetyl-carbamoyl) fumagillol] enhances its antitumor and antiangiogenic efficacies., Journal of Pharmacology and Experimental Therapeutics, 10.1124/jpet.102.043562, 304, 2, 669-674, 304,2,669-674, 2003.02.
100. Akagi, T., Ushinohama, K., Kage, Y., Ishizaki, T., Makinosumi, T., Yamauchi, A., Taguchi, Y., Inoue, K., Yukawa, E., Higuchi, S., Ohdo, S., Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time., Life Sciences, 10.1016/S0024-3205(02)02363-9, 72, 10, 1183-1197, 72,1183-1197, 2003.01.
101. Koyanagi, S., Ohdo, S., Alteration of intrinsic biological rhythms during interferon treatment and its possible mechanism., Molecular Pharmacology, 10.1124/mol.62.6.1393, 62, 6, 1393-1399, 62,6, 1393-1399, 2002.12.
102. Takane, H., Ohdo, S., Baba, R., Koyanagi, S., Yukawa, E., Higuchi, S., Relationship between 24-hr rhythm in antiviral effect of interferon-β and interferon-α/βreceptor expression in mice., Japanese Journal of Pharmacology, 10.1254/jjp.90.304, 90, 4, 304-312, 90,4,304-312, 2002.12.
103. Takata, M., Burioka, N., Ohdo, S., Takane, H., Terazono, H., Miyata, M., Sako, T., Suyama, H., Fukuoka, Y., Tomita, K., Shimizu, E., Daily expression of mRNAs for the mammalian clock genes Per2 and Clock in mouse suprachiasmatic nuclei and liver and human peripheral blood mononuclear cells., Japanese Journal of Pharmacology, 10.1254/jjp.90.263, 90, 3, 263-269, 90,3,263-269, 2002.11.
104. Sonoki, K., Yoshinari, M., Iwase, M., Lino, K., Ichikawa, K., Ohdo, S., Higuchi, S., Iida, M., Glycoxidized low-density lipoprotein enhances monocyte chemoattractant protein-1 mRNA expression in human umbilical vein endothelial cells: relation to lysophosphatidylcholine contents and inhibition by nitric oxide donor. Metabolism 51,9, 1135-1142, 2002., Metabolism, 10.1053/meta.2002.34703, 51, 9, 1135-1142, 51,9, 1135-1142, 2002.09.
105. Suematsu, F., Yukawa, E., Yukawa, M., Minemoto, M., Ohdo, S., Higuchi, S., Goto, Y., Pharmacoepidemiologic detection of calcium channel blocker-induced change on digoxin clearance using multiple trough screen analysis., Biopharmaceutics & Drug Disposition, 10.1002/bdd.306, 23, 5, 173-181, 23,5,173-181, 2002.07.
106. Yukawa, E., Hokazono, T., Yukawa, M., Ichimaru, R., Maki, T., Matsunaga, K., Ohdo, S., Anai, M., Higuchi, S., Goto, Y., Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in japanese patients., Clinical Pharmacokinetics, 10.2165/00003088-200241020-00006, 41, 2, 153-159, 41, 2, 153-159, 2002.02.
107. Yukawa, E., Satou, M., Nonaka, T., Yukawa, M., Ohdo, S., Higuchi, S., Kuroda, T., Goto, Y., Pharmacoepidemiologic investigation of clonazepam relative clearance by mixed-effect modeling using routine clinical pharmacokinetic data in japanese patients., Journal of Clinical Pharmacology, 10.1177/0091270002042001009, 42, 1, 81-88, 42,1,81-88, 2002.01.
108. Yukawa, E., Nonaka, T., Yukawa, M., Ohdo, S., Higuchi, S., Kuroda, T., Goto, Y., Pharmacoepidemiologic investigation of a clonazepam-carbamazepine interaction by mixed effect modeling using routine clinical pharmacokinetics data in japanese patients., Journal of Clinical Psychopharmacology, 10.1097/00004714-200112000-00008, 21, 6, 588-593, 21,6,588-593, 2001.12.
109. Yukawa, E., Suematsu, F., Yukawa, M., Minemoto, M., Ohdo, S., Higuchi, S., Goto, Y., Aoyama, T., Population pharmacokinetics of digoxin in japanese patients: A 2-compartment pharmacokinetic model., Clinical Pharmacokinetics, 10.2165/00003088-200140100-00005, 40, 10, 773-781, 40,10, 773-781, 2001.10.
110. Yukawa, E., Satou, M., Nonaka, T., Yukawa, M., Ohdo, S., Higuchi, S., Kuroda, T., Goto, Y., Influence of age and comedication on steady-state clonazepam serum level-dose ratios in japanese epileptic patients., Journal of Clinical Pharmacy and Therapeutics., 10.1046/j.1365-2710.2001.00372.x, 26, 5, 375-379, 26,5,375-379, 2001.10.
111. Viyoch , J., Ohdo, S., Yukawa, E., Higuchi, S., Dosing time-dependent tolerance of catalepsy by repetitive administration of haloperidol in mice., Journal of Pharmacology and Experimental Therapeutics, 298, 3, 964-969, 298,3, 964-969, 2001.09.
112. Hayashi, N., Aso, H., Higashida, M., Kinoshita, H., Ohdo, S., Yukawa, E., Higuchi, S., Estimation of rhG-CSF absorption kinetics after subcutaneous administration using a modified wagner-nelson method with a nonlinear elimination model., European Journal of Pharmaceutical Sciences, 10.1016/S0928-0987(00)00219-0, 13, 2, 151-158, 13,151-158, 2001.05.
113. Suematsu, F., Yukawa, E., Yukawa, M., Minemoto, M., Ohdo, S., Higuchi, S., Goto, Y., Population-based investigation of relative clearance of digoxin in japanese neonates and infants by multiple-trough screen analysis., European Journal of Clinical Pharmacology, 10.1007/s002280100274, 57, 1, 19-24, 57,1, 19-24, 2001.04.
114. Ohdo, S. , Koyanagi , S., Suyama, H., Higuchi, S., Aramaki, H., Changing the dosing schedule minimizes the disruptive effects of interferon on clock function., Nature Medicine, 10.1038/85507, 7, 3, 356-360, 7,3,356-360, 2001.03.
115. Takane, H., Ohdo, S., Yamada, T., Koyanagi, S., Yukawa, E., Higuchi, S., Relationship between diurnal rhythm of cell cycle and interferon receptor expression in implanted-tumor cells., Life Sciences, 10.1016/S0024-3205(01)00943-2, 68, 12, 1449-1455, 68,1449-1455, 2001.02.
116. Wang, D.S., Ohdo, S., Koyanagi, S., Takane, H., Aramaki, H., Yukawa, E., Higuchi, S., Effect of dosing schedule on pharmacokinetics of alpha interferon and anti-alpha interferon neutralizing antibody in mice., Antimicrobial Agents and Chemotherapy, 10.1128/AAC.45.1.176-180.2001, 45, 1, 176-180, 45,1, 176-180, 2001.01.
117. Yukawa, E., Hokazono, T., Funakoshi, A., Yukawa, M., Ohdo, S., Higuchi, S., Ichimaru, R., Maki, T., Matsunaga, K., Anai, M., Goto, Y., Epidemiologic investigation of the relative clearance of haloperidol by mixed-effect modeling using routine clinical pharmacokinetic data in japanese patients., Journal of Clinical Psychopharmacology, 10.1097/00004714-200012000-00016, 20, 6, 685-690, 20, 6, 685-690, 2000.12.
118. Yukawa, E., Hokazono, T., Satou, M., Ohdo, S., Higuchi, S., Aoyama, T., Pharmacokinetic interactions among phenobarbital, carbamazepine, and valproic acid in pediatric japanese patients: clinical considerations on steady-state serum concentration-dose ratios., American Journal of Therapeutics, 7, 303-308, 2000.09.
119. Ohdo, S., Wang, D.S., Koyanagi, S., Takane, H., Inoue, K., Aramaki, H., Yukawa, E., Higuchi, S., Basis for dosing time-dependent changes in the antiviral activity of interferon-α in mice., Journal of Pharmacology and Experimental Therapeutics, 294, 2, 488-493, 294,2,488-493, 2000.08.
120. Takane, H., Ohdo, S., Yamada, T., Yukawa, E., Higuchi, S., Chronopharmacology of antitumor effect induced by interferon-β in tumor-bearing mice., Journal of Pharmacology and Experimental Therapeutics, 294, 2, 746-752, 294,2,746-752, 2000.08.
121. Terashi, K., Oka, M., Ohdo, S., Furukubo, T., Ikeda, C., Fukuda, M., Soda H., Higuchi, S., Kohno, S., Close association between clearance of recombinant human granulocyte colony-stimulating factor (G-CSF) and G-CSF receptor on neutrophils in cancer patients., Antimicrobial Agents and Chemotherapy, 43, 1, 21-24, 43,1,21-24, 1999.01.
122. Ohdo, S., Ogawa, N.,Song, J.G., Higuchi, S., Chronopharmacological study of Ke-Si-To components in mice., Life Sciences, 10.1016/S0024-3205(98)00177-5, 62, 22, 2057-2064, 62,22,2057-2064, 1998.06.
123. Ohdo, S., Furukubo, T., Arata, N., Yukawa, E., Higuchi, S., Nakano, S., Ogawa, N., Influence of dosing time on pharmacological action of G-CSF in mice. Life Sciences 62,12,PL163-168,1998., Life Sciences, 10.1016/S0024-3205(98)00038-1, 62, 12, PL163-PL168, 62,12,PL163-168, 1998.04.
124. Ohdo, S., Arata, N., Furukubo, T., Yukawa, E., Higuchi, S., Nakano, S., Ogawa, N., Chronopharmacology of granulocyte colony-stimulating factor in mice., Journal of Pharmacology and Experimental Therapeutics, 285, 1, 242-246, 285,1,242-246, 1998.04.
125. Yukawa, E., To, H., Ohdo, S., Higuchi, S., Aoyama, T., Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling., European Journal of Clinical Pharmacology, 10.1007/s002280050423, 54, 1, 69-74, 54,1,69-74, 1998.03.
126. Yukawa, E., To, H., Ohdo, S., Higuchi, S., Aoyama, T., Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics., Journal of Clinical Pharmacology, 37, 12, 1160-1167, 37,12,1160-1167, 1997.12.
127. Ohdo, S., Makinosumi, T., Ishizaki, T., Yukawa, E., Higuchi, S., Nakano, S., Ogawa, N., Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice., Journal of Pharmacology and Experimental Therapeutics, 283, 3, 1383-1388, 283,3,1383-1388, 1997.12.
128. Ohdo, S., Inoue, K., Yukawa, E., Higuchi, S., Nakano, S., Ogawa, N., Chronotoxicity of methotrexate in mice and its relation to circadian rhythm of DNA synthesis and pharmacokinetics., Japanese Journal of Pharmacology, 10.1254/jjp.75.283, 75, 3, 283-290, 75,283-290, 1997.11.
129. oyanagi, S., Ohdo, S., Yukawa, E., Higuchi, S., Chronopharmacological study of interferon-α in mice., Journal of Pharmacology and Experimental Therapeutics, 283, 1, 259-264, 283,1,259-264, 1997.10.
130. Yukawa, E., Honda, T., Ohdo, S., Higuchi, S., Aoyama, T., Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening., Journal of Pharmacy and Pharmacology, 49, 8, 751-756, 49,751-756, 1997.08.
131. Nagatomi, A., Mishima, M., Tsuzuki, O., Ohdo, S., Higuchi, S., Utility of a rectal suppository containing the antiepileptic drug zonisamide., Biological Pharmaceutical Bulletin, 20, 8, 892-896, 20,8,892-896, 1997.08.
132. Ogawa, N., Ohdo, S., Song, J.G., Higuchi, S., Chronopharmacological study of Ke-Si-To in mice., Life Sciences, 60, 23, 2091-2098, 60, 23, 2091-2098, 1997.05.
133. Yukawa, E., Honda, T., Ohdo, S., Higuchi, S., Aoyama, T., Population-based investigation of relative clearance of digoxin in japanese patients by multiple trough screen analysis: an update., Journal of Clinical Pharmacology, 37, 2, 92-100, 37,2,92-100, 1997.02.
134. Yoshiyama Y., Sugiyama, T., Miyazaki, H., Shimada, H., Ohdo, S., Influence of the lighting schedule on the toxicity of doxorubicin in chick embryos., Alternatives to Animal Testing and Experimentation, 4,2,55-61, 1997.02.
135. Ohdo, S., Yukawa, E., Higuchi, S., Nakano, S., Ogawa, N., Chronopharmacokinetics of valproic acid following constant-rate administration in mice; Modification by feeding schedule., Proceedings International Symposium on Controlled Release Bioactive Materials, 583-584, 23, 583-584, 1996.07.
136. Ohdo, S., Ogawa, N., Nakano, S., Higuchi, S., Influence of feeding schedule on the chronopharmacological aspects of sodium valproate in mice., Journal of Pharmacology and Experimental Therapeutics, 278, 1, 74-81, 278,1,74ー81, 1996.07.
137. Ohdo, S., Watanabe, H., Ogawa, N., Yoshiyama, Y., Sugiyama,T., Chronotoxicity of sodium valproate in pregnant mouse and embryo., Japanese Journal of Pharmacology, 10.1254/jjp.70.253, 70, 3, 253-258, 70,30,253ー258, 1996.03.
138. Yoshiyama, Y., Kobayashi, T., Ohdo, S., Ogawa, N., Bergeron, M.G., Labrecque, G., Beauchamp, D.,Nakano, S., Influence of a circadian-stage-dependent dosing schedule on the pharmacokinetics of isepamicin in humans., Journal of Infection and Chemotherapy, 2,106-109, 1996.02.
139. Lee, V.H.L., Yamahara, H., Gurny, R., Sintzel, M.B., Martenet M., Gex-Fabry, M., Balant, L., Ohdo, S., Podder S.K., Basis for dosing time-dependent changes in the ocular and systemic absorption of topically applied timolol., Journal of Ocular Pharmacology and Therapeutics, 12,2,103-113, 1996.02.
140. Ohdo, S., Watanabe, H., Ogawa, N., Yoshiyama, Y., Sugiyama,T., Circadian rhythm of the embryotoxicity induced by sodium valproate in mice., European Journal of Pharmacology, 10.1016/S0922-4106(05)80056-2, 293, 3, 281-285, 293,281ー285, 1995.10.
141. Ohdo, S., Ogawa, N., Song, J.G., Chronopharmacological study of acetylsalicylic acid in mice., European Journal of Pharmacology, 10.1016/S0014-2999(05)80007-X, 293, 2, 151-157, 293,151ー157, 1995.07.
142. Yoshiyama, Y., Sugiyama, T., Kubota, N., Miyazaki, H., Saito, K., Tomonaga, F., Shimada, H., Ohdo, S., Manipulation of lighting schedule can modify the pharmacological effects of theophylline in chick embryos., Biological Pharmaceutical Bulletin, 18, 5, 776-778, 18,5,776ー778, 1995.05.
143. Song, J.G., Ohdo, S., Ogawa, N., Chronopharmacokinetics of valproic acid following constant-rate administration in mice and influence of feeding schedule., Acta Pharmacologica Sinica, 16,2,113-117, 1995.03.
144. Ishikawa, M., Ohdo, S., Watanabe, H., Hara, C., Ogawa, N., Alteration in circadian rhythm of plasma corticosterone in rats following sociopsychological stress induced by communication box., Physiology and Behavior, 57,1,41-47, 1995.01.
145. Song, J.G., Ohdo, S., Ogawa, N., The normal body temperature lowering effect of aspirin in mice and its circadian rhythm., Acta Pharmaceutica Sinica, 29,5,330-334, 1994.05.
146. Song, J.G., Ohdo, S., Nakano, S., Ogawa, N., Influence of feeding schedule on chronopharmacological aspects of gentamicin in mice., Chronobiology International, 10,5,338-348, 1993.10.
147. Yoshiyama, Y., Nishikawa, S., Sugiyama, T., Kobayashi, T., Shimada, H., Tomonaga, F., Ohdo, S., Ogawa, N., Nakano, S., Influence of circadian-stage-dependent dosing schedule on nephrotoxicity and pharmacokinetics of isepamicin in rats., Antimicrobial Agents and Chemotherapy, 37,9,2042-2043, 1993.09.
148. Song, J.G., Nakano, S., Ohdo, S., Ogawa, N., Chronotoxicity and chronopharmacokinetics of methotrexate in mice: modification by feeding schedule., Japanese Journal of Pharmacology, 62,4,373-378, 1993.08.
149. Watanabe, H., Ohdo, S., Ishikawa, M., Ogawa, N., Effects of social isolation on pentobarbital activity in mice: Relationship to racemate levels and enantiomers levels in brain., Journal of Pharmacology and Experimental Therapeutics, 263,3,1036-1045, 1992.12.
150. Ohdo, S., Zhu, J., Lee V.H.L., Light-dark variations in ocular timolol concentrations following topical solution instillation in the pigmented rabbit., Life Sciences, 51,26,2025-2031, 1992.12.
151. Ohdo, S., Nakano, S., Ogawa, N., Circadian changes of valproate kinetics depending on meal condition in man., Journal of Clinical Pharmacology, 32,822-826, 1992.09.
152. Ishikawa, M., Hara, C., Ohdo, S., Ogawa, N., Plasma corticosterone response of rats with socio-psychological stress in communication box., Physiology & Behavior,  52,3,475-480,1992., 1992.09.
153. Yoshiyama, Y., Nakano, S., Ohdo, S., Ogawa, N., Chronopharmacological study of valproic acid in mice: Comparison of oral and rectal administration., Journal of Pharmacobio Dynamics, 15,8,403-408, 1992.08.
154. Lee, V.H.L., Luo, A.M., Li, S., Podder, S.K., Chang, J.S.C., Ohdo, S., Grass, G.M., Pharmacokinetic basis for nonadditivity of intraocular pressure lowering in timolol combinations., Investigative Ophthalmology & Visual Science, 32,11,2948-2957, 1991.10.
155. Ohdo, S., Grass, G.M., Lee, V.H.L., Improving the ocular to systemic ratio of topical timolol by varying the dosing time., Investigative Ophthalmology & Visual Science, 32,10,2790-2798, 1991.09.
156. Ohdo,S.,Nakano,S.,Ogawa,N., Chronopharmacokinetics of valproic acid following constant-rate administration in mice., Chronobiology International, 8,1,35-43, 1991.02.
157. Ohdo,S.,Nakano,S.,Ogawa,N., An influencing factor to predict plasma valproate concentrations: Circadian stage-dependent kinetics., Japanese Journal of Clinical Pharmacology and Therapeutics, O21, 4,747-754, 1990.12.
158. Watanabe,H.,Nakano,S.,Ohdo,S.,Takaoka,N.,Ogawa,N., Time-dependent in diazepam kinetics after repeated doses in man., Japanese Journal of Clinical Pharmacology and Therapeutics, 21,3,579-584, 1990.09.
159. Lee,V.H.L., Ohdo,S.,Podder,S.,Shih,R.L., Maximizing the ratio of ocular to systemic absorption of topically applied timolol in the pigmented rabbit by varying the time of drop instillation., Proceedings International Symposium on Controlled Release Bioactive Materials, 17,218-219, 1990.07.
160. Ohdo,S.,Nakano,S.,Ogawa,N., Circadian stage-dependent changes in valproate kinetics and application to dosage adjustment., Clinical Pharmacology, 6,108-112, 1990.01.
161. Ohdo,S.,Nakano,S.,Ogawa,N., Chronotoxicity of sodium valproate and its mechanisms in mice: Dose-concentration-response relationship., Chronobiology International, 6,3,229-235, 1989.03.
162. Ohdo,S.,Yoshimura,H.,Ogawa,N., Alteration in hypnotic effect of pentobarbital following repeated agonistic confrontations in mice., Psychopharmacology, 97,30-34, 1989.01.
163. Ohdo,S.,Nakano,S.,Ogawa,N., Chronopharmacological study of sodium valproate in mice: Dose-concentration-response relationship., Japanese Journal of Pharmacology, 47,11-19, 1988.05.
164. Nakano,S.,Ohdo,S., Ogawa,N., Manipulation of feeding schedule can modify the circadian rhythms of toxicity and kinetics of theophylline in mice., Annual Review of Chronopharmacology, 5,317-320, 1988.01.
165. Nakano, S.,Watanabe, H.,Ohdo,S.,Ogawa,N., Circadian stage-dependent changes in diazepam and valproate kinetics in man: A single and repetitive administration study., Annual Review of Chronopharmacology, 3,421-424, 1986.01.